Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance

Semin Cancer Biol. 1995 Jun;6(3):135-45. doi: 10.1006/scbi.1995.0016.


The type I growth factor receptor family is increasingly recognized as important in the development and maintenance of breast cancer. The family currently consists of four closely related members: the epidermal growth factor receptor (EGF-R/erbB-1), erbB-2, erbB-3 and erbB-4. Putative ligands which bind directly to or indirectly activate erbB-2/3/4 have been characterized recently. This still growing family of EGF-related growth factors includes gp30, its homolog heregulin (HRG), the rat homolog neu differentiation factor (NDF), glial growth factors (GLIA), ARIA and a 50 kDa factor from COLO 16 cells. The understanding of the function, biology and interactions of these growth factor receptors and their ligands will have far-reaching implications for the prognosis and treatment of breast cancer. This review focuses on advances and future directions for further investigations intended to clarify the mechanism and significance of erbB/ligand interactions in breast cancer.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Breast Neoplasms / ultrastructure*
  • Disease Progression
  • Drug Interactions
  • Drug Resistance, Neoplasm / physiology*
  • ErbB Receptors / physiology*
  • Humans
  • Proto-Oncogene Proteins / physiology*
  • Rats
  • Receptor, ErbB-2 / physiology
  • Receptor, ErbB-3


  • Proto-Oncogene Proteins
  • ErbB Receptors
  • Receptor, ErbB-2
  • Receptor, ErbB-3